Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes - PubMed (original) (raw)
. 2003 Feb 21;278(8):5828-36.
doi: 10.1074/jbc.M208132200. Epub 2002 Dec 16.
Affiliations
- PMID: 12486128
- DOI: 10.1074/jbc.M208132200
Free article
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes
Cinzia Dello Russo et al. J Biol Chem. 2003.
Free article
Abstract
Activation of peroxisome proliferator-activated receptors (PPARs) can regulate brain physiology and provide protection in models of neurological disease; however, neither their exact targets nor mechanisms of action in brain are known. In many cells, PPAR gamma agonists increase glucose uptake and metabolism. Because astrocytes store glucose and provide lactate to neurons on demand, we tested effects of PPAR gamma agonists on astroglial glucose metabolism. Incubation of cortical astrocytes with the PPAR gamma thiazolidinedione (TZD) agonist pioglitazone (Pio) significantly increased glucose consumption in a time- and dose-dependent manner, with maximal increase of 36% observed after 4 h in 30 microm Pio. Pio increased 2-deoxy-glucose uptake because of increased flux through the type 1 glucose transporter. However, at this time point Pio did not increase type 1 glucose transporter expression, nor were its effects blocked by transcriptional or translational inhibitors. Pio also increased astrocyte lactate production as soon as 3 h after incubation. These effects were replicated by other TZDs; however, the order of efficacy (troglitazone > pioglitazone > rosiglitazone) suggests that effects were not mediated via PPAR gamma activation. TZDs increased astrocyte cAMP levels, and their glucose modifying effects were reduced by protein kinase A inhibitors. TZDs inhibited state III respiration in isolated brain mitochondria, whereas in astrocytes they caused mitochondrial membrane hyperpolarization. Pio protected astrocytes against hypoglycemia-induced cell death. Finally, glucose uptake was modified in brain sections prepared from Pio-fed rats. These results demonstrate that TZDs modify astrocyte metabolism and mitochondrial function, which could be beneficial in neurological conditions where glucose availability is reduced.
Similar articles
- Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, Fürnsinn C. Brunmair B, et al. Diabetes. 2001 Oct;50(10):2309-15. doi: 10.2337/diabetes.50.10.2309. Diabetes. 2001. PMID: 11574413 - Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K. Fukunaga Y, et al. Atherosclerosis. 2001 Sep;158(1):113-9. doi: 10.1016/s0021-9150(01)00430-0. Atherosclerosis. 2001. PMID: 11500181 - Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Wang YL, et al. J Biol Chem. 2002 Aug 30;277(35):31781-8. doi: 10.1074/jbc.M204279200. Epub 2002 Jun 24. J Biol Chem. 2002. PMID: 12082115 - [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y, Murase K, Ikeda H. Sugiyama Y, et al. Nihon Rinsho. 2000 Feb;58(2):370-5. Nihon Rinsho. 2000. PMID: 10707560 Review. Japanese. - Metabolic and additional vascular effects of thiazolidinediones.
Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Martens FM, et al. Drugs. 2002;62(10):1463-80. doi: 10.2165/00003495-200262100-00004. Drugs. 2002. PMID: 12093315 Review.
Cited by
- The role of PPAR-γ in memory deficits induced by prenatal and lactation alcohol exposure in mice.
Garcia-Baos A, Pastor A, Gallego-Landin I, de la Torre R, Sanz F, Valverde O. Garcia-Baos A, et al. Mol Psychiatry. 2023 Aug;28(8):3373-3383. doi: 10.1038/s41380-023-02191-z. Epub 2023 Jul 25. Mol Psychiatry. 2023. PMID: 37491462 - Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state.
Koethe D, Rohleder C, Kracht L, Leweke FM. Koethe D, et al. Front Psychiatry. 2023 Mar 3;14:1088459. doi: 10.3389/fpsyt.2023.1088459. eCollection 2023. Front Psychiatry. 2023. PMID: 36937734 Free PMC article. - Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Pizcueta P, Vergara C, Emanuele M, Vilalta A, Rodríguez-Pascau L, Martinell M. Pizcueta P, et al. Int J Mol Sci. 2023 Feb 6;24(4):3201. doi: 10.3390/ijms24043201. Int J Mol Sci. 2023. PMID: 36834611 Free PMC article. Review. - Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Ha J, Choi DW, Kim KJ, Kim KY, Nam CM, Kim E. Ha J, et al. Neurology. 2023 Apr 25;100(17):e1799-e1811. doi: 10.1212/WNL.0000000000207069. Epub 2023 Feb 15. Neurology. 2023. PMID: 36792375 Free PMC article. - Schizophrenia: a disorder of broken brain bioenergetics.
Henkel ND, Wu X, O'Donovan SM, Devine EA, Jiron JM, Rowland LM, Sarnyai Z, Ramsey AJ, Wen Z, Hahn MK, McCullumsmith RE. Henkel ND, et al. Mol Psychiatry. 2022 May;27(5):2393-2404. doi: 10.1038/s41380-022-01494-x. Epub 2022 Mar 9. Mol Psychiatry. 2022. PMID: 35264726 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources